Refine your search
-
Authors
-
Item types
-
Topics
- *Ado-Trastuzumab Emtansine/tu [Therapeutic Use]
- *Angiogenesis Inhibitors/tu [Therapeutic Use]
- *Anthracyclines/tu [Therapeutic Use]
- *Antibiotics, Antineoplastic/tu [Therapeutic Use]
- *Antibodies, Monoclonal, Humanized/tu [Therapeutic Use]
- *Antineoplastic Agents/tu [Therapeutic Use]
- *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
- *Breast Neoplasms/dt [Drug Therapy]
- *Receptor, ErbB-2/ai [Antagonists & Inhibitors]
- *Trastuzumab/tu [Therapeutic Use]
- Ado-Trastuzumab Emtansine/ae [Adverse Effects]
- Antibodies, Monoclonal, Humanized/ae [Adverse Effects]
- Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects]
- Breast Neoplasms/pa [Pathology] [x]
- Disease-Free Survival [x]
- Female
- Humans
- Quality of Life
- Receptor, ErbB-2/me [Metabolism]
- Time Factors
- Show more
- Show less
-
Collections
-
Languages